Financhill
Buy
54

PRCT Quote, Financials, Valuation and Earnings

Last price:
$58.17
Seasonality move :
15.11%
Day range:
$56.00 - $60.02
52-week range:
$47.04 - $103.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.06x
P/B ratio:
8.04x
Volume:
554.1K
Avg. volume:
796.1K
1-year change:
-7.88%
Market cap:
$3.1B
Revenue:
$224.5M
EPS (TTM):
-$1.70

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PRCT
PROCEPT BioRobotics
$75.7M -$0.41 41.82% -20.57% $76.88
CATX
Perspective Therapeutics
$170.4K -$0.29 -- -55.87% $14.1071
RVP
Retractable Technologies
-- -- -- -- --
VNRX
VolitionRX
$375.7K -$0.05 6.24% -40.63% $2.93
VTAK
Catheter Precision
$310K -$0.20 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$31.4M -$0.02 4.73% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PRCT
PROCEPT BioRobotics
$56.57 $76.88 $3.1B -- $0.00 0% 12.06x
CATX
Perspective Therapeutics
$3.3900 $14.1071 $251.6M -- $0.00 0% 23.89x
RVP
Retractable Technologies
$0.64 -- $19.2M -- $0.00 0% 0.57x
VNRX
VolitionRX
$0.77 $2.93 $79.1M -- $0.00 0% 52.93x
VTAK
Catheter Precision
$0.23 -- $2.6M 0.40x $0.00 0% 2.67x
XTNT
Xtant Medical Holdings
$0.72 $1.75 $99.6M -- $0.00 0% 0.80x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PRCT
PROCEPT BioRobotics
12.09% 1.535 1.66% 7.60x
CATX
Perspective Therapeutics
-- 1.363 -- --
RVP
Retractable Technologies
1.48% -0.677 12.06% 4.40x
VNRX
VolitionRX
-29.91% 3.387 11.38% 0.34x
VTAK
Catheter Precision
17.75% -1.532 53.57% 0.13x
XTNT
Xtant Medical Holdings
43.24% 1.491 51.14% 0.96x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PRCT
PROCEPT BioRobotics
$44.2M -$27.4M -24.95% -29.12% -34.5% -$18.8M
CATX
Perspective Therapeutics
-- -$21.8M -- -- -- -$26.2M
RVP
Retractable Technologies
-$1.9K -$3.2M -25.99% -26.39% -122.86% -$1.6M
VNRX
VolitionRX
-- -$5.4M -- -- -2183.56% -$4.3M
VTAK
Catheter Precision
$132K -$3.5M -126.5% -137.84% -3300.7% -$2.3M
XTNT
Xtant Medical Holdings
$20.2M $1.1M -15.44% -26.62% 3.28% $87K

PROCEPT BioRobotics vs. Competitors

  • Which has Higher Returns PRCT or CATX?

    Perspective Therapeutics has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of --. PROCEPT BioRobotics's return on equity of -29.12% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PRCT
    PROCEPT BioRobotics
    63.85% -$0.45 $442.7M
    CATX
    Perspective Therapeutics
    -- -$0.25 --
  • What do Analysts Say About PRCT or CATX?

    PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 35.89%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 316.14%. Given that Perspective Therapeutics has higher upside potential than PROCEPT BioRobotics, analysts believe Perspective Therapeutics is more attractive than PROCEPT BioRobotics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRCT
    PROCEPT BioRobotics
    6 2 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is PRCT or CATX More Risky?

    PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

  • Which is a Better Dividend Stock PRCT or CATX?

    PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRCT or CATX?

    PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than Perspective Therapeutics quarterly revenues of --. PROCEPT BioRobotics's net income of -$24.7M is lower than Perspective Therapeutics's net income of -$18.2M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 12.06x versus 23.89x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRCT
    PROCEPT BioRobotics
    12.06x -- $69.2M -$24.7M
    CATX
    Perspective Therapeutics
    23.89x -- -- -$18.2M
  • Which has Higher Returns PRCT or RVP?

    Retractable Technologies has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of -126.59%. PROCEPT BioRobotics's return on equity of -29.12% beat Retractable Technologies's return on equity of -26.39%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRCT
    PROCEPT BioRobotics
    63.85% -$0.45 $442.7M
    RVP
    Retractable Technologies
    -0.02% -$0.35 $77.8M
  • What do Analysts Say About PRCT or RVP?

    PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 35.89%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that PROCEPT BioRobotics has higher upside potential than Retractable Technologies, analysts believe PROCEPT BioRobotics is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRCT
    PROCEPT BioRobotics
    6 2 0
    RVP
    Retractable Technologies
    0 0 0
  • Is PRCT or RVP More Risky?

    PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.357, suggesting its more volatile than the S&P 500 by 35.696%.

  • Which is a Better Dividend Stock PRCT or RVP?

    PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

  • Which has Better Financial Ratios PRCT or RVP?

    PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than Retractable Technologies quarterly revenues of $8.3M. PROCEPT BioRobotics's net income of -$24.7M is lower than Retractable Technologies's net income of -$10.5M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 12.06x versus 0.57x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRCT
    PROCEPT BioRobotics
    12.06x -- $69.2M -$24.7M
    RVP
    Retractable Technologies
    0.57x -- $8.3M -$10.5M
  • Which has Higher Returns PRCT or VNRX?

    VolitionRX has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of -2201.34%. PROCEPT BioRobotics's return on equity of -29.12% beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PRCT
    PROCEPT BioRobotics
    63.85% -$0.45 $442.7M
    VNRX
    VolitionRX
    -- -$0.06 -$22.6M
  • What do Analysts Say About PRCT or VNRX?

    PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 35.89%. On the other hand VolitionRX has an analysts' consensus of $2.93 which suggests that it could grow by 282.86%. Given that VolitionRX has higher upside potential than PROCEPT BioRobotics, analysts believe VolitionRX is more attractive than PROCEPT BioRobotics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRCT
    PROCEPT BioRobotics
    6 2 0
    VNRX
    VolitionRX
    2 1 0
  • Is PRCT or VNRX More Risky?

    PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

  • Which is a Better Dividend Stock PRCT or VNRX?

    PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRCT or VNRX?

    PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than VolitionRX quarterly revenues of $246.4K. PROCEPT BioRobotics's net income of -$24.7M is lower than VolitionRX's net income of -$5.4M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 12.06x versus 52.93x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRCT
    PROCEPT BioRobotics
    12.06x -- $69.2M -$24.7M
    VNRX
    VolitionRX
    52.93x -- $246.4K -$5.4M
  • Which has Higher Returns PRCT or VTAK?

    Catheter Precision has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of -2828.67%. PROCEPT BioRobotics's return on equity of -29.12% beat Catheter Precision's return on equity of -137.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRCT
    PROCEPT BioRobotics
    63.85% -$0.45 $442.7M
    VTAK
    Catheter Precision
    92.31% -$0.36 $9.6M
  • What do Analysts Say About PRCT or VTAK?

    PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 35.89%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 761.7%. Given that Catheter Precision has higher upside potential than PROCEPT BioRobotics, analysts believe Catheter Precision is more attractive than PROCEPT BioRobotics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRCT
    PROCEPT BioRobotics
    6 2 0
    VTAK
    Catheter Precision
    0 0 0
  • Is PRCT or VTAK More Risky?

    PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.724, suggesting its less volatile than the S&P 500 by 172.434%.

  • Which is a Better Dividend Stock PRCT or VTAK?

    PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRCT or VTAK?

    PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than Catheter Precision quarterly revenues of $143K. PROCEPT BioRobotics's net income of -$24.7M is lower than Catheter Precision's net income of -$4M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 12.06x versus 2.67x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRCT
    PROCEPT BioRobotics
    12.06x -- $69.2M -$24.7M
    VTAK
    Catheter Precision
    2.67x 0.40x $143K -$4M
  • Which has Higher Returns PRCT or XTNT?

    Xtant Medical Holdings has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of 0.18%. PROCEPT BioRobotics's return on equity of -29.12% beat Xtant Medical Holdings's return on equity of -26.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRCT
    PROCEPT BioRobotics
    63.85% -$0.45 $442.7M
    XTNT
    Xtant Medical Holdings
    61.52% -- $77.3M
  • What do Analysts Say About PRCT or XTNT?

    PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 35.89%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 144.76%. Given that Xtant Medical Holdings has higher upside potential than PROCEPT BioRobotics, analysts believe Xtant Medical Holdings is more attractive than PROCEPT BioRobotics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRCT
    PROCEPT BioRobotics
    6 2 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is PRCT or XTNT More Risky?

    PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

  • Which is a Better Dividend Stock PRCT or XTNT?

    PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRCT or XTNT?

    PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. PROCEPT BioRobotics's net income of -$24.7M is lower than Xtant Medical Holdings's net income of $58K. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 12.06x versus 0.80x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRCT
    PROCEPT BioRobotics
    12.06x -- $69.2M -$24.7M
    XTNT
    Xtant Medical Holdings
    0.80x -- $32.9M $58K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Why Is Goldman Sachs Stock Up So Much?
Why Is Goldman Sachs Stock Up So Much?

Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 40.18% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is down 22.06% over the past day.

Buy
67
GBX alert for Jul 3

Greenbrier Companies [GBX] is up 21.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock